Prognostic significance of proline, glutamic acid, leucine rich protein 1 (PELP1) in triple-negative breast cancer: a retrospective study on 129 cases

BMC Cancer

Research Article

Bing Bai¹  Yanchun Xing²  Shuwen Cao³  Xiuli Wang⁴  Yinli Song⁴  Xiaolei Li⁴  Jiali Dai⁴  Mumu Shi⁴  Lijuan Liu⁴  Ying Ma⁴  Baoshan Zhao⁴  Lin Wang⁴  Yanzhi Zhang⁴  Ming Liu⁵  Keely M. McNamara⁶  Monica S. M. Chan⁶  Hironobu Sasano⁶ 

[1] Department of Histology and Biology, Harbin Medical University-Daqing, Daqing, China;Department of Pathology, Daqing Longnan Hospital, Daqing, China;Department of Pathology, Daqing Oilfield General Hospital, Daqing, China;Department of Pathology, Harbin Medical University-Daqing, No. 39 Xinyang Road, Hi-Tech Zone, Daqing, Heilongjiang, China;Department of Pathology, Harbin Medical University-Daqing, No. 39 Xinyang Road, Hi-Tech Zone, Daqing, Heilongjiang, China;Department of Pathology, The Fifth Affiliated Hospital of Harbin Medical University, Daqing, China;Department of Pathology, Tohoku University School of Medicine, Sendai, Japan;

关键词: Proline;    Glutamic acid;    Leucine rich protein 1;    Triple negative breast cancer;    Prognosis;    Immunohistochemistry;   

DOI  :  10.1186/s12885-015-1694-y

 received in 2015-03-02, accepted in 2015-10-07,  发布年份 2015

来源: Springer

【 摘 要 】

BackgroundTriple-negative breast cancer (TNBC) is associated with an aggressive clinical course due to the lack of therapeutic targets. Therefore, identifying reliable prognostic biomarkers and novel therapeutic targets for patients with TNBC is required. Proline, glutamic acid, leucine rich protein 1 (PELP1) is a novel steroidal receptor co-regulator, functioning as an oncogene and its expression is maintained in estrogen receptor (ER) negative breast cancers. PELP1 has been proposed as a prognostic biomarker in hormone-related cancers, including luminal-type breast cancers, but its significance in TNBC has not been studied.MethodsPELP1 immunoreactivity was evaluated using immunohistochemistry in 129 patients with TNBC. Results were correlated with clinicopathological variables including patient’s age, tumor size, lymph node stage, tumor grade, clinical stage, histological type, Ki-67 LI, as well as clinical outcome of the patients, including disease-free survival (DFS) and overall survival (OS).ResultsPELP1 was localized predominantly in the nuclei of carcinoma cells in TNBC. With the exception of a positive correlation between PELP1 protein expression and lymph node stage (p = 0.027), no significant associations between PELP1 protein expression and other clinicopathological variables, including DFS and OS, were found. However, when PELP1 and Ki-67 LI were grouped together, we found that patients in the PELP1/Ki-67 double high group (n = 48) demonstrated significantly reduced DFS (p = 0.005, log rank test) and OS (p = 0.002, log rank test) than others (n = 81). Multivariable analysis supported PELP1/Ki-67 double high expression as an independent prognostic factor in patients with TNBC, with an adjusted hazard ratio of 2.020 for recurrence (95 % CL, 1.022–3.990; p = 0.043) and of 2.380 for death (95 % CL, 1.138–4.978; p = 0.021).ConclusionsWe found that evaluating both PELP1 and Ki-67 expression in TNBC could enhance the prognostic sensitivity of the two biomarkers. Therefore, we propose that PELP1/Ki-67 double high expression in tumors is an independent prognostic factor for predicting a poor outcome for patients with TNBC.

【 授权许可】

CC BY   
© Zhang et al. 2015